Effect of a milk formula containing probiotics on the fecal microbiota of asian infants at risk of atopic diseases

Pediatr Res. 2007 Dec;62(6):674-9. doi: 10.1203/PDR.0b013e31815991d5.

Abstract

The fecal microbiota of 37 infants with (n = 20) or without (n = 17) probiotic administration was evaluated on D 3, and at 1, 3, and 12 mo by fluorescence in situ hybridization-flow cytometry (FISH-FC), PCR, and bacteriological culture methods. They represent consecutive subjects of an ongoing double-blind, placebo-controlled trial on a probiotic formula (LGG and Bifidobacterium longum) administered during the first 6 mo of life. Despite varying composition in each baby, there was a general bacterial colonization pattern in the first year. Bifidobacteria increased markedly (p = 0.0003) with a parallel decrease in Enterobacteriaceae (p < 0.001) and Bacteroides-Prevotella (p = 0.005) populations. Eubacterium rectale-Clostridium coccoides (p < 0.001) and Atopobium (p = 0.039) groups also gradually increased. This overall pattern was unaffected by probiotic administration (p > 0.05). B. longum (p = 0.005) and Lactobacillus rhamnosus (p < 0.001) were detected more frequently in probiotic group during supplementation, but no difference after supplementation had ceased (p > 0.05). Cultured lactic acid bacteria were also more numerous in the probiotic-administered babies during treatment period (log CFU/g 8.4 versus 7.4; p = 0.035). Our results indicate that supplemented strains could be detected but did not persist in the bowel once probiotic administration had ceased.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asian People*
  • Bacteriological Techniques
  • Bacteroides / growth & development
  • Bifidobacterium* / genetics
  • Bifidobacterium* / growth & development
  • Clostridium / growth & development
  • DNA, Bacterial / analysis
  • Double-Blind Method
  • Enterobacteriaceae / growth & development
  • Eubacterium / growth & development
  • Feces / microbiology*
  • Female
  • Flow Cytometry
  • Gastrointestinal Tract / microbiology*
  • Gestational Age
  • Humans
  • Hypersensitivity, Immediate / microbiology*
  • In Situ Hybridization, Fluorescence
  • Infant
  • Infant Formula / administration & dosage*
  • Infant, Newborn
  • Lacticaseibacillus rhamnosus* / genetics
  • Lacticaseibacillus rhamnosus* / growth & development
  • Male
  • Polymerase Chain Reaction
  • Prevotella / growth & development
  • Probiotics / administration & dosage*
  • Risk Assessment
  • Risk Factors
  • Time Factors

Substances

  • DNA, Bacterial